We note that activation of mTOR is also observed in rodent models of other peripheral neuropathies displaying hypermyelination, e.g. recessive CMT4B caused by mutations in the phosphoinositide lipid phosphatases myotubularin-related protein 2 (MTMR2) and 13 (MTMR13) genes (Azzedine et al, 2003; Bolino et al, 2000; Guerrero-Valero et al, 2021; Houlden et al, 2001) which are also targets of Rapamycin therapy (Bolino et al, 2016). This evidence concerns the gene PTPMT1 and peripheral neuropathy.